𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma

✍ Scribed by Michael J. Shulman; Elie A. Benaim

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
149 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Selective aromatase inhibition for patie
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma : A Phase II study of letrozole
✍ Matthew R. Smith; Donald Kaufman; Daniel George; William K. Oh; Maryanne Kazanis πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 2 views

## Background: First and second-generation aromatase inhibitors have shown activity in patients with androgen-independent prostate carcinoma. these early-generation aromatase inhibitors are nonselective, however, and inhibition of other steroidogenic enzymes may contribute to their reported clinica

Mental state as a possible independent p
Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma
✍ Yasuharu Nakahara; Yoshiro Mochizuki; Yoshihiro Miyamoto; Akira Tanaka; Tetsuji πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 129 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Although psychologic factors have been reported to influence the progression of cancer, this theory remains controversial. A prospective study of patients with advanced lung carcinoma was performed to explore the influence of the patient's mental state on survival. ## ME

Multicenter Phase II study of estramusti
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma
✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho

A Phase II trial of green tea in the tre
A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
✍ Aminah Jatoi; Neil Ellison; Patrick A. Burch; Jeff A. Sloan; Shaker R. Dakhil; P πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## Background: Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. this phase ii trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. ## Methods: This study, whi